Related Experiment Video
Updated: Jul 18, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Brain aminopeptidases and hypertension
Inmaculada Banegas1, Isabel Prieto, Francisco Vives
1Unit of Physiology, University of Jaén, Spain.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 10, 2006
Summary
Brain aminopeptidases are key to regulating blood pressure (BP). Inhibiting glutamyl aminopeptidase (GluAP) offers a new hypertension treatment strategy by targeting angiotensin III, a crucial BP regulator.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Brain aminopeptidases are integral to the renin-angiotensin system, influencing blood pressure (BP) control.
- Angiotensin II is metabolized to angiotensin III (Ang III) by glutamyl aminopeptidase (GluAP), and Ang III is critical for central BP regulation.
Purpose of the Study:
- To explore the role of brain aminopeptidases in central BP control.
- To investigate the therapeutic potential of targeting brain aminopeptidases, specifically GluAP, for hypertension treatment.
Main Methods:
- Enzymatic assays to study aminopeptidase activity in the brain.
- Analysis of the renin-angiotensin system cascade and its effect on BP.
- Investigation of brain asymmetry and its correlation with aminopeptidase activity and BP.
Main Results:
- Angiotensin III (Ang III) is identified as the primary active form of central angiotensins, exerting tonic stimulatory control over BP.
- Glutamyl aminopeptidase (GluAP) inhibitors show promise as antihypertensive agents.
- A link between brain asymmetry, aminopeptidase activity, and BP control is suggested.
Conclusions:
- Targeting brain aminopeptidases, particularly GluAP, presents a novel therapeutic avenue for hypertension.
- Understanding the interplay between brain aminopeptidases, asymmetry, and BP control is crucial for advancing hypertension management.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:18Neural Regulation of Blood Pressure
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...